Table 1.
Variable | Total n/N0 | Outcome at 30 days after‐admission | P‐value | Crude hazard ratio (95% CI) | |
---|---|---|---|---|---|
Survivors n/N1 (%) | Nonsurvivors n/N2 (%) | ||||
SIRS | 72/138 | 38/92 (41) | 34/46 (74) | <.001 | 5.0 (2.3‐10.8) |
Coagulation disorders | 13/97 | 4/63 (6) | 9/34 (26) | .006 | 2.9 (1.4‐6.4) |
Metabolic acidosis | 32/85 | 12/51 (24) | 20/34 (59) | <.001 | 3.2 (1.6‐6.4) |
Hepatic injury | 67/124 | 46/88 (52) | 21/36 (58) | .51 | 1.3 (0.7‐2.6) |
Increased creatinine | 64/138 | 19/92 (21) | 27/46 (59) | <.001 | 3.7 (2.0‐6.7) |
Hyperkalemia | 15/130 | 5/85 (6) | 10/45 (22) | .020 | 2.4 (1.0‐5.7) |
Ionized hypocalcemia | 26/96 | 8/62 (13) | 18/34 (53) | <.001 | 4.7 (2.3‐9.4) |
Hyperglycemia | 16/122 | 7/84 (8) | 9/38 (24) | .011 | 2.7 (1.3‐5.6) |
Hypoalbuminemia | 62/101 | 41/71 (58) | 21/30 (70) | .048 | 1.9 (1.0‐4.1) |
Spec‐cPL > 1000 μg/L | 41/138 | 22/92 (24) | 19/46 (41) | .054 | 1.8 (1.0‐3.2) |
Age (years) | 138/138 | 11.3 (range, 1‐16) | 9.3 (range, 2.3‐20) | .67 | 1.3 (0.7‐2.4) |
Abbreviations: CI, confidence interval; N, number of dogs for which the abnormality was investigated (N0 total, N1 survivor, N2 nonsurvivor); n, number of dogs presenting the laboratory or clinical abnormality; SIRS, systemic inflammatory response syndrome